35 Essential Thought Leaders in Pharmaceuticals Globally

Introduction

The pharmaceutical industry is having a conversation that most people cannot hear. Behind the headlines about drug prices and breakthrough approvals, there is a parallel world of researchers, executives, advocates, journalists, and policy architects who are quietly shaping what medicines get developed, who can access them, and whether the public trusts them enough to use them. These are the people worth following. Not because they manage the biggest budgets or lead the most famous companies, but because their ideas about how the industry should work are actively changing how it does work.

Here is the counterintuitive truth about pharmaceutical thought leadership in 2026: the most consequential voices are not always in the C-suites of Big Pharma. Some of the most important thinking is happening in academic labs developing low-cost vaccines without patents, in policy institutes modelling new financing mechanisms for drug development, and in independent media holding the industry accountable with precision and candour. The global pharmaceutical market is projected to surpass $1.75 trillion in prescription drug sales by 2030, according to Evaluate Pharma's 2025 World Preview. A sector of that scale needs more than executives. It needs thinkers, critics, advocates, and innovators willing to ask whether the system is working for the people it claims to serve.

This list brings together 35 such voices. It spans chief executives and academic scientists, policy architects and patient advocates, AI drug discovery founders and independent journalists. It includes voices from the United States, Europe, India, Africa, and the Asia-Pacific region. It deliberately reaches beyond the familiar names of the largest pharmaceutical companies to capture the thinkers who are shaping what the industry looks like a decade from now. If you work in pharmaceuticals, invest in biotech, lead a healthcare organisation, or simply want to understand the forces driving one of the most consequential industries on earth, these are the people worth following.

To bring these ideas to life inside your leadership team or board, consider bringing in a facilitator who can translate the insights these thinkers champion into the decisions and conversations your organisation needs to have right now. Jonno White, bestselling author of Step Up or Step Out and Certified Working Genius Facilitator, works with leadership teams across healthcare, corporate, and not-for-profit sectors. To discuss how Jonno might support your team, email jonno@consultclarity.org.

Why Pharmaceutical Thought Leadership Matters

The pharmaceutical industry is arguably the most consequential industry in human history, and it is under greater pressure than at any point in living memory. In 2025 alone, the sector absorbed a wave of US tariff uncertainty, the dramatic rise of GLP-1 therapies for obesity and diabetes, a looming patent cliff worth over $300 billion in sales at risk by 2030, seismic shifts at the US Food and Drug Administration, and an accelerating war against vaccine science in the political mainstream. Navigating this environment requires more than operational competence. It requires ideas.

Pharmaceutical thought leaders are the people generating those ideas. They are the academics whose research reshapes how clinical trials are designed. They are the executives willing to speak publicly about pricing ethics, not just pipeline performance. They are the advocates who refuse to let access to medicines be treated as a secondary concern after profitability. They are the journalists who hold billion-dollar companies accountable with evidence rather than anecdote. When the right ideas circulate through an industry, the industry gets better. Patients wait less time for treatments. Medicines reach more people. Trust in the science deepens.

Ignoring the leading thinkers in this space carries a real cost. Organisations that treat thought leadership as noise rather than signal are consistently slower to anticipate regulatory shifts, slower to build the cultural infrastructure for genuine patient centricity, and slower to position themselves for the technology transitions reshaping drug discovery. The voices in this guide are the early signal. Following them is not about keeping up with trends. It is about being inside the conversation that determines what comes next.

How This List Was Compiled

This list was assembled through a structured research process focused on genuine intellectual contribution to the global pharmaceuticals conversation. Every person included meets a clear standard: they are actively shaping how the industry thinks, not just commenting on what it does. The selection criteria prioritised authentic expertise in their specific domain, whether that domain is drug pricing, clinical innovation, AI in drug discovery, medicines access, vaccine development, regulatory affairs, or pharmaceutical investment.

The final 35 represent geographic diversity across the United States, United Kingdom, Europe, India, Africa, and the Asia-Pacific region. Disciplinary diversity was also a primary consideration: the list spans Big Pharma executives, academic researchers, independent journalists, policy advocates, investment analysts, and technology founders. No single company, institution, or perspective dominates. The ambition was to produce a list that would be genuinely useful to a pharmaceutical executive in Mumbai or Melbourne, not just a reader in New York or London.

Category 1: The Science and Innovation Architects

These thought leaders are at the frontier of drug discovery, biologics innovation, and the scientific ideas that drive the next generation of medicines. Their work in laboratories, clinical programmes, and research institutions is setting the agenda for what pharmaceutical R&D looks like in the decade ahead.

1. Vas Narasimhan | Novartis

One of the most articulate executives in the global pharmaceutical industry, Vasant "Vas" Narasimhan has led Novartis since 2018 with a clear and consistent conviction that medicines companies must be powered by data, digital technology, and a genuine commitment to improving patient lives. A physician by training, Narasimhan brings clinical credibility to strategic decisions that most pharmaceutical CEOs cannot match, giving his public commentary unusual authority at the intersection of science and business.

His intellectual contribution to the field centres on the integration of AI and data science into the core operating model of a major pharmaceutical company. In late 2025, Narasimhan oversaw Novartis's proposed acquisition of Avidity Biosciences for approximately $12 billion, part of a buying spree of more than 35 companies over the preceding twelve months. His advocacy for what he calls "unbossed" leadership, reflecting his thinking on building psychological safety within large scientific organisations, has influenced how pharma leaders at multiple companies approach culture, talent, and innovation.

2. George Yancopoulos | Regeneron

The co-founder and Chief Scientific Officer of Regeneron Pharmaceuticals, George Yancopoulos is one of the most productive drug discovery scientists in the history of the industry, responsible for a platform that has generated some of the most impactful medicines of the past two decades. His long partnership with Regeneron co-founder Leonard Schleifer has produced a model of research-led pharmaceutical innovation that many organisations study but few successfully replicate.

Among his most significant contributions to the field is the VelociSuite technology platform, which Regeneron developed to accelerate antibody drug discovery and which has been licensed to multiple major pharmaceutical companies. Yancopoulos has published more than 100 peer-reviewed scientific papers and holds numerous patents underlying medicines across oncology, immunology, ophthalmology, and rare disease. His persistent argument that deep scientific investment, not fast dealmaking, is the foundation of sustainable pharmaceutical value creation makes him one of the most important voices on what excellent drug discovery actually looks like.

3. Katalin Karikó | University of Pennsylvania

Few careers in pharmaceutical science carry the narrative weight of Katalin Karikó's. For decades, the Hungarian-born biochemist persisted in researching mRNA as a potential therapeutic platform despite institutional rejection, funding cuts, and professional demotion. When the COVID-19 pandemic arrived, the mRNA platform she co-developed with Drew Weissman became the foundation of the most rapidly developed vaccines in history. In 2023, she and Weissman were awarded the Nobel Prize in Physiology or Medicine.

Their foundational scientific paper, published together in 2005 in the journal Immunity, described the modification of mRNA nucleosides to reduce immune activation, a discovery that made therapeutic mRNA viable. Karikó now serves as an adjunct professor of neurosurgery at the University of Pennsylvania and continues to engage with the global scientific community as mRNA platforms expand into cancer vaccines, HIV treatments, and rare disease therapies. Her story is simultaneously a lesson in scientific persistence and an illustration of how pharmaceutical progress depends on ideas that are initially dismissed.

4. Reshma Kewalramani | Vertex Pharmaceuticals

The President and Chief Executive Officer of Vertex Pharmaceuticals, Reshma Kewalramani leads one of the most scientifically focused and financially successful mid-sized pharmaceutical companies in the world. Vertex's approach to drug development, which centres on deeply understanding the biology of specific diseases and pursuing medicines that address the underlying genetic cause rather than simply managing symptoms, has produced some of the most transformative medicines in the history of rare disease treatment, including the cystic fibrosis triple therapy Trikafta.

A physician-scientist by training with a background in nephrology, Kewalramani brings clinical credibility and scientific rigour to her public commentary on what pharmaceutical innovation should look like. In late 2023, Vertex launched Casgevy, the first CRISPR-based gene-editing therapy for sickle-cell disease, developed in collaboration with CRISPR Therapeutics. Named Time Woman of the Year for 2026, her visibility as a senior woman of colour in the pharmaceutical CEO community makes her one of the most significant voices in the industry.

5. Eric Topol | Scripps Research

The founder and director of the Scripps Research Translational Institute, Eric Topol is one of the most trusted and most active voices in evidence-based healthcare at the intersection of medicine, artificial intelligence, and clinical practice. A cardiologist with deep research credentials, he has spent two decades advocating for a more patient-centred, data-rich model of healthcare in which individuals have genuine access to their own clinical data and AI tools augment rather than replace clinical judgment.

His 2019 book Deep Medicine, published by Basic Books, outlined the case for AI as a transformative tool in clinical practice and became one of the most widely read books on technology and healthcare among both clinicians and industry executives. Topol has since continued his work on AI and medicine through the Ground Truths newsletter on Substack, which reaches hundreds of thousands of readers globally, and his peer-reviewed research on AI diagnostic tools has influenced regulatory discussions at the FDA and beyond.

6. Daphne Koller | Insitro

The co-founder and CEO of Insitro, Daphne Koller brings a background as a Stanford computer science professor and Coursera co-founder to the challenge of applying machine learning at scale to drug discovery. Her conviction that the pharmaceutical industry's historically low R&D productivity is fundamentally a data problem, not a science problem, has made her one of the most compelling voices on how artificial intelligence can reshape the entire drug development pipeline, not just specific steps within it.

Insitro, the company she founded in 2018, is built on the principle of generating proprietary biological datasets at scale and using machine learning to extract insights that traditional drug discovery methods cannot produce. Koller's academic work on probabilistic machine learning, developed over her years at Stanford and articulated across more than 300 peer-reviewed publications, informs both the technical direction of her company and the broader conversation about what meaningful AI integration in biotech actually requires. Her public commentary on what distinguishes genuine AI capability from AI branding has become a trusted reference point for investors, executives, and scientists evaluating the AI in pharma landscape.

7. Andrew Hopkins | Exscientia

The founder and former CEO of Exscientia, Andrew Hopkins is one of the pioneers of AI-designed drug discovery, a field he has been shaping since before it had a name. Originally a professor of medicinal informatics at the University of Dundee, Hopkins built Exscientia into the company that ran what is widely regarded as the first AI-designed drug molecule to enter clinical trials in humans, a milestone that reframed the industry's understanding of what machine learning could contribute to the drug discovery process.

Hopkins's academic work on polypharmacology, the idea that drugs often need to interact with multiple biological targets to be effective, laid the scientific foundation for Exscientia's computational approach. His public commentary on the realistic timeline for AI to fundamentally change pharmaceutical productivity distinguishes him from more promotional voices in the space: he emphasises rigour, data quality, and the irreducible importance of medicinal chemistry expertise alongside computational methods.

Category 2: The Regulatory and Policy Architects

These are the thinkers who shape the rules of the pharmaceutical game: the regulatory frameworks that determine which drugs reach patients, the pricing structures that determine who can afford them, and the public health policies that govern whether the industry's products are trusted and used.

8. Scott Gottlieb | American Enterprise Institute

The 23rd Commissioner of the US Food and Drug Administration, Scott Gottlieb served from 2017 to 2019 and has since become one of the most widely read and quoted voices in pharmaceutical policy in the English-speaking world. His prolific output across CNBC commentary, Wall Street Journal columns, board service at Pfizer, and his work at the American Enterprise Institute has made him a genuine bridge figure between the regulatory world, the investment community, and the media.

During his tenure at the FDA, Gottlieb oversaw a significant acceleration in drug approvals, launched the FDA's Drug Competition Action Plan targeting generic drug delays, and was an early voice on the opioid crisis. Since leaving the FDA, he published Uncontrolled Spread (HarperCollins, 2021), examining lessons from the COVID-19 pandemic for future pandemic preparedness. His daily commentary on drug regulation, pricing, and public health policy reaches tens of thousands of followers across LinkedIn and social media.

9. Aaron Kesselheim | Harvard Medical School

A professor of medicine at Harvard Medical School and director of the Program On Regulation, Therapeutics, and Law, Aaron Kesselheim is one of the most rigorous and widely cited scholars working on pharmaceutical policy, drug pricing, and the regulation of pharmaceutical markets. His research combines legal analysis, health economics, and clinical evidence to produce some of the clearest thinking available on why medicines cost what they do and what policy tools can change that.

His research published in the New England Journal of Medicine and JAMA has shaped Congressional discussions on drug pricing reform, including the debates that led to the Inflation Reduction Act's provision allowing Medicare to negotiate drug prices directly with manufacturers. Kesselheim's work on the effects of drug market exclusivity periods and pay-for-delay settlements in the generic drug sector has made him a reference source for journalists, policymakers, and patient advocates trying to understand the structural forces that keep medicine prices high.

10. Nathalie Moll | EFPIA

As Director General of the European Federation of Pharmaceutical Industries and Associations, Nathalie Moll is the principal voice for the research-based pharmaceutical industry in Europe, representing more than 40 leading pharmaceutical companies and 33 national associations. Her role positions her at the centre of some of the most consequential policy conversations in the global pharmaceutical industry, from the EU Pharmaceutical Package and the Critical Medicines Act to the EU's joint health technology assessment process.

Moll has been a persistent advocate for a regulatory environment in Europe that supports pharmaceutical innovation while ensuring genuine patient access, and her public commentary on the tension between pricing sustainability and R&D investment incentives is among the most sophisticated available in the policy space. Her work navigating the competing priorities of payers, health technology assessment bodies, patient organisations, and pharmaceutical companies has made EFPIA under her leadership one of the most influential industry voices in European health policy.

11. Jayasree K. Iyer | Access to Medicine Foundation

As Executive Director of the Access to Medicine Foundation, Jayasree K. Iyer leads one of the most respected independent organisations tracking and evaluating how pharmaceutical companies perform on access to medicine in low and middle income countries. The Foundation's Access to Medicine Index, which assesses the world's largest pharmaceutical companies on their efforts to make medicines accessible, has become a reference tool for investors, regulators, and health advocates worldwide.

Iyer's intellectual contribution to the pharmaceutical field is in bringing rigorous, evidence-based measurement to a part of the industry's responsibility that is often assessed through press releases rather than data. Her organisation's research has found that while pharmaceutical companies have improved performance on some access dimensions, significant gaps remain in the availability of essential medicines in the poorest markets. Her commentary on the conditions under which pharmaceutical innovation and equitable access can coexist makes her one of the most important voices in the global health policy conversation.

Category 3: The Voices for Access, Equity, and Public Health

These thought leaders centre their work on the question that most pharmaceutical industry conversations treat as secondary: who can actually use the medicines being developed, and at what cost to their lives and families? Their arguments have shifted both policy and practice in measurable ways.

12. Peter Hotez | Baylor College of Medicine

The Dean of the National School of Tropical Medicine at Baylor College of Medicine and co-director of the Texas Children's Hospital Center for Vaccine Development, Peter Hotez is simultaneously one of the most important vaccine scientists in the world and one of its most courageous public advocates for evidence-based medicine. He has spent decades developing low-cost vaccines for neglected tropical diseases affecting hundreds of millions of people in the Global South, diseases largely ignored by the commercial pharmaceutical industry because they primarily afflict populations without purchasing power.

Hotez and his colleague Maria Elena Bottazzi co-developed the Corbevax COVID-19 vaccine, a protein subunit vaccine deliberately designed without patents so that it could be produced affordably at scale in low-income countries. The vaccine has been administered to tens of millions of people in India and Indonesia. His 2025 book Science Under Siege, co-authored with climate scientist Michael E. Mann, documents the forces driving the anti-science movement and what can be done about it. His willingness to continue this advocacy under sustained personal harassment makes him one of the most distinctive voices in the pharmaceutical and public health field.

13. Maria Elena Bottazzi | Baylor College of Medicine

The co-director of the Texas Children's Hospital Center for Vaccine Development and associate dean of the National School of Tropical Medicine at Baylor College of Medicine, Maria Elena Bottazzi has spent her career at the junction of vaccine science and global health equity. Born in Honduras, she brings a personal understanding of what it means to live in a country that depends on the generosity of wealthy nations for access to medicines, and that lived experience informs the rigour and urgency of her scientific work.

Alongside Peter Hotez, Bottazzi led the development of Corbevax, the low-cost patent-free COVID-19 vaccine that became one of the most widely administered COVID vaccines in the developing world. Her work on neglected tropical disease vaccines including vaccines for schistosomiasis, Chagas disease, and leishmaniasis has been recognised by the WHO. In 2022, she and Hotez were nominated for the Nobel Peace Prize in recognition of their efforts to develop and distribute COVID vaccines for the world's poorest populations, a nomination that drew global attention to the question of whether the commercial pharmaceutical model adequately serves global public health.

14. Kiran Mazumdar-Shaw | Biocon

The founder and Executive Chairperson of Biocon, one of India's largest biopharmaceutical companies, Kiran Mazumdar-Shaw has built a global enterprise focused on making oncology and diabetes medicines accessible in markets that the traditional pharmaceutical model tends to underserve. Her conviction that biologics and biosimilars can be produced at a fraction of current market prices while maintaining clinical quality has driven Biocon's strategy and influenced how the industry thinks about pricing in emerging markets.

She was named to Forbes' World's 100 Most Powerful Women list in 2025 and has been a consistent voice for pharmaceutical innovation that serves both commercial sustainability and social purpose. Biocon Biologics, the company's biosimilar business, initiated a planned integration with the parent company in December 2025 in a deal valuing Biocon Biologics at $5.5 billion, creating a unified biopharma powerhouse. Mazumdar-Shaw's advocacy for affordable innovation represents one of the most developed frameworks for thinking about how the pharmaceutical industry can simultaneously reward investment and fulfil its social mandate.

15. Suerie Moon | Graduate Institute Geneva

The co-director of the Global Health Centre at the Graduate Institute of International and Development Studies in Geneva, Suerie Moon is one of the world's leading scholars on global health governance, pharmaceutical access, and the international policy frameworks that shape who can access medicines and at what price. Her research sits at the intersection of political science, international law, and public health policy, giving her commentary on pharmaceutical issues an unusual institutional grounding.

Her work on the World Health Organization's Pandemic Influenza Preparedness Framework and on the governance of the Access to COVID-19 Tools Accelerator has influenced how governments, international organisations, and civil society groups think about the conditions that enable more equitable pharmaceutical access. Moon has published extensively in journals including The Lancet, Health Affairs, and the Journal of International Economic Law. Her arguments about the need for more transparent and accountable governance of pharmaceutical innovation are increasingly central to discussions about how the system should be reformed.

16. Ellen 't Hoen | Medicines Law & Policy

A Dutch lawyer and global health advocate who has spent decades at the intersection of intellectual property law, pharmaceutical access, and trade policy, Ellen 't Hoen is one of the most influential voices in the world on the legal and structural mechanisms that determine whether life-saving medicines reach the people who need them. She is the founder of Medicines Law & Policy and a former director of the Medicines Patent Pool.

Her foundational work on compulsory licensing, the legal mechanism that allows governments to override pharmaceutical patents to produce or import generic versions of medicines in public health emergencies, has shaped international law, WHO policy, and the global response to the HIV/AIDS crisis and COVID-19 pandemic. Her book Private Patents and Public Health, co-authored with Health Action International, is a definitive reference on how patent law shapes access to medicines. Her continuing advocacy for the reform of intellectual property norms to better serve global health needs makes her one of the most genuinely consequential figures in pharmaceutical policy.

17. Raj Nair | Cipla

The CEO of Cipla, one of the world's most important generic and specialty pharmaceutical companies, Raj Nair leads an organisation whose history is inseparable from the access-to-medicines movement. Cipla's offer in 2001 to supply generic antiretrovirals for HIV/AIDS treatment at $1 per day per patient effectively broke the financial model of inaccessible patented medicines in the developing world and triggered a transformation in how the global community thought about access to life-saving drugs.

Under Nair's leadership, Cipla continues to expand its portfolio of affordable oncology, respiratory, and specialty medicines in markets across Africa, Asia, and increasingly in the United States. His advocacy for building pharmaceutical manufacturing capacity in emerging markets rather than depending on global supply chains that fail in crises has gained particular relevance in the post-pandemic environment and in the context of ongoing discussions about pharmaceutical supply chain resilience.

18. Rajiv Shah | The Rockefeller Foundation

The President of The Rockefeller Foundation, Rajiv Shah brings a career spanning global health finance, vaccine access, and international development to his role leading one of philanthropy's oldest and most influential institutions. A physician and health economist by training, Shah served as Administrator of USAID under President Obama from 2010 to 2015, where he led the US response to the Haiti earthquake and the West African Ebola pandemic, and championed funding structures that dramatically expanded global vaccine access.

His 2023 book Big Bets: How Large-Scale Change Really Occurs draws on decades of experience in global health and development to argue for a model of change that combines ambitious goal-setting, rigorous data, and authentic partnership rather than incremental reform. At the Rockefeller Foundation, Shah has championed health systems strengthening as a core priority, building on the Foundation's historic role in global pharmaceutical and public health infrastructure. His perspective on what pharmaceutical access and health equity look like at a genuinely global scale makes him one of the most important non-industry voices in the pharmaceutical thought leadership conversation.

19. Mark Duman | MD Healthcare

The founder of MD Healthcare and one of the most active and widely connected patient engagement professionals in the pharmaceutical industry, Mark Duman has spent more than two decades building frameworks, tools, and communities that help pharmaceutical companies move from patient-centric language to patient-centric practice. His work as a speaker, facilitator, and adviser to major pharmaceutical companies has reached professionals across Europe, North America, and the Asia-Pacific region.

Duman has pioneered the Patient Engagement Quality Framework, a practical tool used by pharmaceutical companies to assess and improve the quality of their patient engagement activities across the drug development and commercialisation lifecycle. His LinkedIn activity is among the most engaged in the patient centricity space, and his willingness to constructively challenge pharmaceutical companies when their patient engagement efforts are performative rather than substantive gives his commentary a credibility that purely internal advocates cannot achieve.

Category 4: The Financial and Investment Intelligence

These are the thinkers who shape how capital flows through the pharmaceutical industry, how investors evaluate drug development risk, and how the financial structures of pharmaceutical innovation can be reformed to produce better outcomes for patients and innovators alike.

20. Peter Kolchinsky | RA Capital Management

A managing partner of RA Capital Management and one of the most widely read investor-thinkers in the biotechnology sector, Peter Kolchinsky brings a distinctive combination of scientific training and investment expertise to his public commentary on pharmaceutical pricing, drug development economics, and the social compact between pharmaceutical innovators and the patients they serve. His 2019 booklet The Great American Drug Deal laid out a framework for understanding pharmaceutical pricing that has been cited by both industry advocates and policy reformers.

Kolchinsky argues that the pharmaceutical social compact is fundamentally a deal in which companies receive a period of high-margin returns on successful drugs in exchange for the ongoing risk-taking and investment required to develop new ones, and that reforming this compact requires understanding both its legitimate functions and its genuine failures. His regular posts on LinkedIn and Twitter about specific drug pricing decisions, FDA approvals, and biotech investment dynamics reach tens of thousands of readers in the investment and pharmaceutical communities.

21. Andrew Lo | MIT Sloan

A professor of finance at the MIT Sloan School of Management and director of the MIT Laboratory for Financial Engineering, Andrew Lo has spent over a decade developing and advocating for novel financial structures that could transform how pharmaceutical R&D is funded. His most significant contribution to the field is his research on pharmaceutical innovation funds and megafunds, which use financial engineering to diversify the risk of drug development across large portfolios of compounds in ways that could dramatically reduce the cost of capital for pharmaceutical research.

His research on the economics of oncology drug development, published in Science and Science Translational Medicine, has influenced policy discussions at the FDA, the National Institutes of Health, and the US Congress about how to stimulate innovation in areas where market incentives are currently insufficient. Lo's arguments about what structural changes to pharmaceutical finance would produce a more functional innovation ecosystem are among the most rigorous available from an economist who has engaged seriously with the specific biology and economics of drug development.

22. Luke Timmerman | Timmerman Report

The founder and editor of The Timmerman Report and one of the most respected independent voices in biotechnology and pharmaceutical journalism, Luke Timmerman has spent more than two decades covering the industry with a combination of scientific literacy, investment knowledge, and editorial courage that is rare in specialist media. His newsletter and podcast reach a loyal audience of biotechnology investors, executives, and scientists who value analysis over press release journalism.

Timmerman's regular feature TR Conversations has produced some of the most candid and substantive interviews available with pharmaceutical executives, scientists, and investors. His book Hood: Trailblazer of the Genomics Age, a biography of biotech pioneer Leroy Hood published by Timmerman Report, exemplifies his approach of using long-form narrative to illuminate the science and human stories behind pharmaceutical innovation.

23. Jeremy Levin | Ovid Therapeutics

The CEO of Ovid Therapeutics, a biopharmaceutical company focused on rare neurological diseases, Jeremy Levin is one of the most articulate and experienced executives in the pharmaceutical and biotechnology industries, with a career spanning senior roles at Bristol Myers Squibb, Teva Pharmaceuticals, and a range of advisory and board positions. His public commentary on pharmaceutical dealmaking, R&D productivity, and the relationship between scientific ambition and commercial strategy is among the most sophisticated available from a sitting executive.

Levin has been a persistent advocate for a more collaborative model of pharmaceutical innovation in which academic research, small biotechs, and large pharmaceutical companies operate as genuine partners rather than in an adversarial transaction model. His leadership of Ovid, which focuses on rare neurological diseases with high unmet need and no existing treatments, puts his argument about pharmaceutical purpose into operational practice.

Category 5: The Science Communicators and Industry Media

These are the journalists, media founders, commentators, and analysts who make the pharmaceutical world legible to practitioners, investors, and the public. Without their work, the ideas produced by researchers and executives circulate only in specialist silos.

24. Paul Tunnah | pharmaphorum

The founder and CEO of pharmaphorum, one of the pharmaceutical industry's most respected digital media platforms, Paul Tunnah has spent more than fifteen years building a publication and community that helps pharmaceutical professionals engage with the ideas shaping their industry. His platform gives voice to a wide range of perspectives on pharmaceutical innovation, market access, patient centricity, digital health, and industry leadership.

Tunnah's work in building pharmaphorum from a small digital publication into a global platform for pharmaceutical thought leadership has itself been a contribution to how the industry learns and communicates. His podcast series and editorial work have reached pharmaceutical professionals across more than 100 countries, and his ability to curate and connect voices across the scientific, commercial, regulatory, and patient advocacy dimensions of the industry makes him a genuine bridge figure in the pharmaceutical knowledge ecosystem.

25. Adam Feuerstein | STAT News

A senior journalist at STAT News, Adam Feuerstein has spent more than two decades covering biotech with a level of scepticism, scientific literacy, and market knowledge that has made him one of the most influential commentators in the sector. His willingness to challenge the claims of pharmaceutical companies and to write critically about the quality of clinical trial data has repeatedly moved stock prices and shaped the way the investment community evaluates pharmaceutical announcements.

Feuerstein's work at STAT has produced some of the most consequential pharmaceutical journalism of the past decade, including detailed analysis of clinical trial data, FDA advisory committee proceedings, and corporate governance at biotechnology companies. For professionals who want to understand how pharmaceutical claims are evaluated by sophisticated independent observers, his work is essential reading.

26. John LaMattina | Drug Truths

A former president of Pfizer Global Research and Development with more than three decades of pharmaceutical R&D experience, John LaMattina has built a second career as one of the most consistently credible commentators on pharmaceutical innovation, drug pricing, and the economics of pharmaceutical R&D through his Drug Truths blog on Forbes. His insider perspective on what drug development actually costs and what drives pharmaceutical pricing decisions gives his commentary a grounding in operational reality that academic and policy commentators often lack.

LaMattina's willingness to engage directly with critics of the pharmaceutical industry, including those who argue that pharmaceutical profits are unjustified given the role of public funding in basic research, distinguishes him from more defensive industry voices. His assessment of pharmaceutical R&D productivity trends and his commentary on FDA policy changes are consistently cited by media and industry analysts.

27. Derek Lowe | Novartis / In the Pipeline

A medicinal chemist at Novartis and the author of In the Pipeline, one of the longest-running and most widely read blogs on drug discovery and pharmaceutical science, Derek Lowe has spent more than two decades providing scientists, executives, investors, and interested non-specialists with candid, technically sophisticated commentary on what the pharmaceutical industry does well, what it does badly, and why the drug discovery process is so much harder than it looks from the outside.

His writing on the history of drug development failures, the challenges of translating biological discoveries into viable drug candidates, and the often-misunderstood role of medicinal chemistry in the drug discovery process has shaped how a generation of pharmaceutical scientists and investors understand the industry. His willingness to name and explain failures, including high-profile clinical trial disasters that companies prefer to discuss obliquely, makes In the Pipeline one of the most trusted resources in pharmaceutical science communication.

Category 6: The Architects of Digital and AI-Driven Pharma

These voices are defining how artificial intelligence, machine learning, and data science are transforming pharmaceutical R&D, clinical development, and commercial strategy. Their ideas about what genuine AI transformation in pharma requires are increasingly defining the R&D priorities and capital allocation decisions of the industry's largest players.

28. Shannon Thyme Klinger | Novartis

The Chief Legal and Ethics Officer at Novartis, Shannon Thyme Klinger is one of the most visible and articulate voices in the pharmaceutical industry on the ethical dimensions of digital transformation, artificial intelligence, and data use in healthcare. Her work at Novartis has focused on building what she describes as a culture of curiosity and integrity, ensuring that as the company integrates AI into its operations, it does so within a framework of genuine ethical accountability rather than compliance-as-optics.

Klinger has been a persistent advocate for the pharmaceutical industry to engage transparently with the ethical questions raised by AI in drug development, including questions about data privacy, algorithmic bias, and the governance of AI systems that inform clinical decisions. Her public writing and speaking on pharmaceutical ethics and culture has reached a significant audience across the industry and the broader business world.

29. Murali Doraiswamy | Duke University

A professor of psychiatry and medicine at Duke University and co-director of the Duke Centre for the Study of Aging and Human Development, Murali Doraiswamy is one of the most active and publicly engaged voices on AI in neuropsychiatry, Alzheimer's disease research, and the intersection of technology with mental health treatment. His research on biomarkers for Alzheimer's disease and on digital health technologies for mental health makes him a distinctive presence in the pharmaceutical conversation about how technology can address diseases of the ageing brain.

Doraiswamy has been a consistent voice for scientific rigour in the evaluation of AI claims in healthcare, distinguishing between genuine capability and hype. He has authored or co-authored more than 200 peer-reviewed scientific publications and has advised governments, pharmaceutical companies, and international organisations on neurological drug development and digital health strategy.

30. Fiona Murray | MIT

A professor of entrepreneurship at the MIT Sloan School of Management and associate dean for innovation and inclusion, Fiona Murray is one of the world's leading scholars on the conditions that enable scientific innovation to translate into commercially and socially valuable outcomes in the life sciences. Her research on the economics of academic entrepreneurship, on the patent system's effects on biomedical innovation, and on diversity in science and innovation has had direct impact on how universities, governments, and pharmaceutical companies think about building the institutional infrastructure for pharmaceutical progress.

Murray's work on the anti-commons in biomedical research, which examines how excessive fragmentation of intellectual property rights can slow rather than accelerate pharmaceutical innovation, has influenced technology transfer policy at major research universities and at funding agencies including the National Institutes of Health. Her research on gender and racial diversity in pharmaceutical innovation has added an important equity dimension to the conversation about what structural reforms would make pharmaceutical innovation both more productive and more inclusive.

Category 7: The Global Health and Emerging Voice Leaders

These thought leaders represent the regions and perspectives most likely to shape the future of pharmaceutical access, manufacturing, and innovation, including the rapidly growing pharmaceutical industries of South and East Asia, the access challenges of Africa and Latin America, and the governance bodies navigating global health crises.

31. Justine Rochon | Boehringer Ingelheim

Named one of Reuters' Top 10 Trailblazing Women in Pharma 2025, Justine Rochon serves as Senior Vice President of Global Biostatistics and Data Science at Boehringer Ingelheim and is one of the most compelling voices in the pharmaceutical industry on purpose-driven leadership, the integration of data science into pharmaceutical R&D, and what it means to build teams that combine analytical rigour with genuine human values.

Rochon's specific intellectual contribution to the pharmaceutical field is in the methodology and governance of biostatistics and data science within large pharmaceutical R&D programmes, a domain that is technically demanding and frequently underappreciated in executive conversations about pharmaceutical innovation. Her advocacy for women and younger professionals in pharmaceutical science, and her emphasis on building networks of mutual support and purpose, makes her commentary relevant across both the technical and leadership dimensions of pharmaceutical practice.

32. Daria Donati | Roche

A senior oncology executive at Roche, one of the world's largest and most influential pharmaceutical companies in the cancer treatment space, Daria Donati brings deep expertise in oncology clinical development and pharmaceutical strategy to a company whose medicines include some of the world's most impactful cancer therapies. Her work within Roche's oncology portfolio sits at the frontier of personalised cancer treatment, where companion diagnostics, biomarker-driven patient selection, and combination therapies are redefining what pharmaceutical success in oncology can look like.

Roche has consistently been a leader in advancing the field of biomarker-driven oncology and in arguing for a more personalised approach to cancer drug development that identifies the specific patient populations most likely to benefit from specific treatments. Donati's engagement with the scientific and strategic dimensions of this work, and her participation in the broader oncology thought leadership community, makes her a relevant and substantive voice for pharmaceutical professionals working in or investing in oncology.

33. Mene Pangalos | AstraZeneca

As Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, Mene Pangalos leads one of the most productive pharmaceutical R&D engines in the industry, responsible for a portfolio that spans cardiovascular disease, respiratory conditions, metabolic diseases, and vaccines. His leadership of AstraZeneca's COVID-19 vaccine programme during the pandemic gave him a global profile, and his subsequent commentary on the lessons of that programme for pharmaceutical R&D efficiency and the relationship between academia, government, and industry has been substantive and widely cited.

Pangalos has been particularly articulate on the question of how large pharmaceutical companies can maintain the urgency, speed, and scientific boldness of pandemic-era R&D in normal operating conditions. His advocacy for academic-industry collaboration as a genuine driver of pharmaceutical productivity reflects his own career trajectory from academic neuroscientist to pharmaceutical executive and gives his arguments a credibility that purely commercial executives cannot replicate.

34. Albert Bourla | Pfizer

The Chairman and Chief Executive Officer of Pfizer, Albert Bourla led the company through one of the most consequential pharmaceutical achievements in recent history: the development of a COVID-19 vaccine in partnership with BioNTech in less than a year. A veterinarian by training with a PhD in biotechnology of reproduction, Bourla brings an unusual scientific background to the CEO role and uses his platform consistently to argue for the importance of pharmaceutical innovation and scientific evidence in public life.

His book Moonshot: Inside Pfizer's Nine-Month Race to Make the Impossible Possible, published in 2022, documented the decision-making and organisational culture that enabled Pfizer to achieve its pandemic response milestone. In late 2025, Bourla oversaw Pfizer's $10 billion acquisition of Metsera, transforming the company's obesity strategy, and has continued to project that the global obesity medicines market will reach $150 billion by 2030.

35. Jonno White | Consult Clarity

The ideas that the 34 thought leaders above generate are worth nothing if the organisations responsible for acting on them cannot translate insight into decision and decision into action. Jonno White is a Brisbane-based leadership consultant, Certified Working Genius Facilitator, and bestselling author of Step Up or Step Out with over 10,000 copies sold, who works with leadership teams across healthcare, pharmaceutical, corporate, and not-for-profit organisations globally. He brings to the pharmaceutical leadership conversation a practical focus on the human dimensions of organisational performance: how teams have the difficult conversations that determine strategy, how leaders create cultures in which genuine innovation is possible, and how organisations navigate the change pressures that the leaders on this list describe.

Jonno has worked with leadership teams across Australia, the UK, USA, India, Canada, and New Zealand, and his Working Genius facilitation helps teams understand how to build on complementary strengths rather than be frustrated by differences. For pharmaceutical leadership teams that want to move from following the ideas on this list to acting on them, email jonno@consultclarity.org.

Notable Voices We Almost Included

Several credentialled and active pharmaceutical thought leaders were seriously considered for this list but did not make the final 35. Stephane Bancel, CEO of Moderna, is among the most important executives in the mRNA space, but his LinkedIn presence leans toward institutional announcements rather than the kind of substantive independent intellectual contribution that distinguishes the strongest voices on this list. Ugur Sahin, co-founder and CEO of BioNTech, is one of the most important scientists in the history of mRNA therapeutics, but his public engagement is primarily through institutional channels rather than regular original content production. Emma Walmsley, who served as CEO of GSK until December 2025, is a genuinely influential figure in the history of pharmaceutical leadership but her departure from that role at the time of research made her current position and organisational affiliation unclear.

Robert Califf, the former FDA Commissioner who returned to Duke University after his second term ended in 2025, has contributed significantly to the pharmaceutical policy conversation, but his focus has shifted toward academic research rather than active public commentary since leaving the FDA. Frances Arnold, the Nobel laureate chemist and directed evolution pioneer at Caltech, brings extraordinary scientific credentials but her primary domain is adjacent to rather than central to the pharmaceutical thought leadership conversation this list addresses.

Common Mistakes to Avoid When Engaging with Pharmaceutical Thought Leadership

The first common mistake is treating thought leadership as entertainment rather than intelligence. Following impressive-sounding voices on LinkedIn or attending keynote presentations generates a feeling of engagement without necessarily producing any change in how decisions get made. The pharmaceutical executives, scientists, and advocates on this list are useful not because they are interesting to read but because their ideas, when properly digested and tested against your own context, can genuinely improve how you think about pharmaceutical strategy, access, innovation, and leadership.

The second mistake is following only voices that confirm your existing perspective on the industry. If you work in pharmaceutical innovation and only follow innovators, you will miss the access advocates whose arguments increasingly shape regulatory and payer decisions. If you work in health economics and only follow economists, you will miss the AI founders whose work is rewiring the assumptions on which your models are based. The most valuable thought leaders are often the ones from outside your immediate functional discipline.

The third mistake is confusing follower counts with intellectual substance. The pharmaceutical thought leaders with the highest public profiles are often the most global in recognition and the least likely to engage meaningfully with mid-sized organisations or conferences outside their core circuit. Several of the most valuable voices on this list have significantly smaller audiences than their more famous peers, precisely because their thinking is more specialised and their engagement is more selective.

The fourth mistake is engaging with thought leaders only at the point of consumption rather than the point of contribution. Reading is not enough. The most productive way to engage with the voices on this list is to share their work with colleagues who need to hear it, to apply their frameworks in actual decisions, and where appropriate to respond to their posts with your own perspective and experience.

The fifth mistake is treating this list as static. The pharmaceutical industry moves quickly and the people best placed to illuminate its direction are constantly evolving their thinking. Revisit your following list regularly and be willing to stop following voices whose work has become repetitive or institutionally constrained. Fresh perspective matters more than brand recognition.

Implementation Guide: Building Your Pharmaceutical Thought Leadership Practice

The first step is to identify the two or three domains within pharmaceutical thought leadership most relevant to your current professional challenges. This list spans drug discovery, regulatory policy, access and equity, financial innovation, science communication, digital transformation, and global health. No individual or organisation needs to follow all of these conversations with equal depth. Start where your decisions are being made.

The second step is to create a deliberate following practice across multiple platforms. LinkedIn is the most relevant platform for professional pharmaceutical thought leadership, but Twitter and Substack host important conversations that do not always make it to LinkedIn. Set aside fifteen minutes each morning to scan the posts of your highest-priority voices rather than relying on algorithmic feeds to surface them for you. Algorithms optimise for engagement, not for the ideas you most need to encounter.

The third step is to engage rather than only consume. When a voice on this list publishes something that genuinely challenges your thinking or confirms something you have observed, respond in the comments with a specific and substantive observation. Pharmaceutical thought leaders are more likely to develop the depth of their public commentary when they know that substantive practitioners are reading and responding.

The fourth step is to bring these ideas inside your organisation. Create internal forums, whether book clubs, journal clubs, or strategic briefings, where the ideas of the best outside thinkers are regularly examined against the realities of your specific organisation.

The fifth step is to invest in the leadership infrastructure that enables your organisation to actually act on what it learns. The most common failure mode is a gap between insight and action: teams understand what the best thinkers are saying, but lack the alignment, communication quality, and decision-making discipline to translate that understanding into changed behaviour. Jonno White works with leadership teams across the pharmaceutical, healthcare, and corporate sectors to build exactly that infrastructure. To explore how Jonno might support your team, email jonno@consultclarity.org. International travel is often far more affordable than organisations expect.

Frequently Asked Questions

What makes someone a genuine pharmaceutical thought leader rather than just a senior executive? Genuine pharmaceutical thought leadership is demonstrated by the quality and independence of ideas rather than by title or company size. A thought leader generates original frameworks, asks uncomfortable questions, publishes in peer-reviewed journals or widely read independent platforms, and is willing to say things that are inconvenient for the industry or for their employer. Executives who primarily communicate through press releases and earnings calls, however impressive their track records, are not thought leaders in the meaningful sense.

How do I follow and engage with the people on this list? Start with LinkedIn, where most of the people on this list are active and where commenting is relatively low-friction. Follow each person directly rather than waiting for algorithmic recommendations. For deeper engagement, subscribe to newsletters or podcasts where available: Luke Timmerman's Timmerman Report, Eric Topol's Ground Truths on Substack, and Peter Kolchinsky's writing are particularly rich resources. Attend webinars and virtual events where these voices appear and ask substantive questions.

How was this list compiled? This list was assembled through a structured process that assessed formal credentials in each person's specific domain, the geographic and disciplinary diversity of the selection, active contribution to the pharmaceutical discourse through publishing, speaking, or public commentary, and the genuine impact of their ideas on how the industry operates. Every person included is an active contributor to the pharmaceutical conversation in 2025 and 2026.

Can I hire someone to facilitate pharmaceutical leadership workshops or sessions for my team? Yes. Jonno White, Certified Working Genius Facilitator and bestselling author, works with leadership teams across the healthcare and pharmaceutical sectors to facilitate sessions on team dynamics, organisational culture, difficult conversations, and strategic alignment. His work helps teams move from following the ideas of the thinkers on this list to actually acting on them within the specific context of their organisation. Many organisations find that flying Jonno in costs less than engaging high-profile local providers. Email jonno@consultclarity.org to discuss your needs.

Which of these thought leaders should I follow first? The answer depends entirely on your professional focus. If you work in pharmaceutical policy or pricing, begin with Aaron Kesselheim, Ellen 't Hoen, and Suerie Moon. If you work in pharmaceutical R&D or AI in drug development, begin with Eric Topol, Daphne Koller, and George Yancopoulos. If you work in market access or patient centricity, begin with Jayasree K. Iyer, Mark Duman, and Nathalie Moll. If you work in pharmaceutical investment or business development, begin with Peter Kolchinsky, Luke Timmerman, and Andrew Lo.

Are there pharmaceutical thought leaders from outside North America and Europe worth following? Absolutely, and this list was deliberately designed to include them. Kiran Mazumdar-Shaw from India's Biocon represents the emerging market pharmaceutical innovation perspective. Raj Nair leads Cipla, whose history of challenging the affordability model of pharmaceutical access is essential context for understanding global pharmaceutical policy. Maria Elena Bottazzi's background in Honduras and her work on vaccines for the Global South adds a genuinely different perspective on what pharmaceutical progress should look like. Following these voices alongside the better-known North American and European voices will significantly improve the geographic diversity of your pharmaceutical thought leadership intake.

Final Thoughts

The pharmaceutical industry is at an inflection point. The science of drug discovery is accelerating, with AI beginning to compress timelines that have historically stretched across decades. The policy environment is turbulent, with pricing pressures in the United States, regulatory reform in Europe, and a new generation of access debates reshaping what it means for a medicine to be commercially successful. The public trust environment is fragile, with misinformation about vaccines and pharmaceutical products threatening the uptake of medicines that genuinely save lives.

The 35 voices assembled in this guide are the people trying to make sense of these pressures and chart a path through them. They span the scientific, commercial, policy, advocacy, and communications dimensions of an industry that needs all of these perspectives working together. Following them will not make your decisions for you. But it will ensure that your decisions are informed by the best available thinking rather than by internal assumptions that go unchallenged.

Jonno White, Certified Working Genius Facilitator and bestselling author of Step Up or Step Out with over 10,000 copies sold, works with leadership teams in the pharmaceutical, healthcare, and corporate sectors to help them build the organisational infrastructure to act on what they learn. Whether virtual or face to face, reach out to jonno@consultclarity.org to explore how he might support your team.

About the Author

Jonno White is a Certified Working Genius Facilitator, bestselling author, and leadership consultant who has worked with schools, corporates, and nonprofits across the UK, India, Australia, Canada, Mongolia, New Zealand, Romania, Singapore, South Africa, USA, Finland, Namibia, and more. His book Step Up or Step Out has sold over 10,000 copies globally, and his podcast The Leadership Conversations has featured 230+ episodes reaching listeners in 150+ countries. Jonno founded The 7 Questions Movement with 6,000+ participating leaders and achieved a 93.75% satisfaction rating for his Working Genius masterclass at the ASBA 2025 National Conference. Based in Brisbane, Australia, Jonno works globally and regularly travels for speaking and facilitation engagements. Organisations consistently find that international travel is far more affordable than expected.

To book Jonno for your next keynote, workshop, or facilitation session, email jonno@consultclarity.org.

Next Read

For more on finding the right leadership support for healthcare organisations, check out my blog post '50 Top Leadership Consultants for Healthcare (2026)' at the link below.

https://www.consultclarity.org/post/50-top-leadership-consultants-for-healthcare-2026